Clesrovimab is an RSV fusion protein-directed monoclonal antibody that provides passive immunity against RSV infection in infants. Clesrovimab is a fully human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody targeted against the extracellular domain of the respiratory syncytial virus (RSV) fusion (F) protein.
- Mechanism
- Curator reviewed · 2 references
Clesrovimab binds to a conserved epitope on antigenic site IV on the RSV fusion (F) protein. Binding of clesrovimab physically prevents fusion of the viral membrane with the host cell membrane, thereby preventing viral entry.
- Primary indication
- Clesrovimab-cfor is indicated for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection in neonates and infants who are born during or entering their first RSV season.Curator reviewed · 1 structured indication
- Formula / weight
- 149000.0 Da
- First approval
- Canada, 2026 · United States, 2025
- Also known as
- Immunoglobulin g1 (262-tyrosine,264-threonine,266-glutamic acid), anti-(human respiratory syncytial virus f protein) (human monoclonal rb1 .gamma.1-chain), disulfide with human monoclonal rb1 .kappa.-chain, dimer
- Code names
- MK-1654
- Brand names
Resolves to
What you can answer from here — as of September 21, 2026
Which drugs share a target with Clesrovimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account